JBF Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

JBF Capital’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-20,000	Closed	-$113K	–	89
2024 Q2	$113K	Buy	+20,000	New	+$103K	0.02%	80

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JBF Capital's VNDA Position: Q3 2024 in Review

JBF Capital sold out of Vanda Pharmaceuticals (VNDA) in Q3 2024, closing a stake of 20,000 shares — an estimated $113K sold.

JBF Capital first reported a position in VNDA in Q2 2024 and held it in 1 quarter. The position peaked at $113K in Q2 2024. 152 funds tracked by Wall St. Rank hold VNDA as of Q3 2024.

JBF Capital reported no remaining Vanda Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
JBF Capital sold 20,000 Vanda Pharmaceuticals shares in Q3 2024, an estimated $113K.
JBF Capital first reported a position in Vanda Pharmaceuticals in Q2 2024 and held it in 1 quarter.
JBF Capital's Vanda Pharmaceuticals position peaked at $113K in Q2 2024.
152 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2024.

Based on JBF Capital's 13F filing for Q3 2024, filed 14 Nov 2024.